Disclosed is a use of a polypeptide compound having dual agonistic effects on the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). The polypeptide compound has the characteristics of a high enzymolysis stability, a high biological activity and zero adverse reaction, etc., can obviously inhibit the fibrosis transformation and proliferation of human pulmonary epithelial cells induced by TGF-β1, and can obviously improve the degree of pulmonary fibrosis in mice induced by bleomycin. Such a dual target agonist polypeptide can be used for preventing or treating pulmonary diseases indicated by fibrotic symptoms.
展开▼
